# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with co...
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.
- Reuters
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clini...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.